Short answer
Moderna (MRNA) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Moderna announced third-quarter 2026 financial results for the period ended September 30, 2026.
Moderna 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Moderna announced third-quarter 2026 financial results for the period ended September 30, 2026
- Exhibit 99.1 contains the detailed earnings release for revenue, profitability, and outlook analysis
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.3B, up 29%, with international COVID vaccine sales driving growth
- GAAP net income $162M, diluted EPS $0.38, reversing Q3 2025’s $200M loss
- 2026 revenue-growth outlook raised to 15%–25%, from up to 10% previously
- 2026 cash-and-investments outlook increased to $8.1B–$8.3B, supported by $2.6B convertible-note proceeds
- Intismeran plus KEYTRUDA reduced melanoma recurrence or death risk 42%, strengthening oncology’s commercial potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Moderna 8-K filings
Get the next MRNA 8-K as it lands
Follow MRNA for push alerts, or ask the research agent what this filing means.